The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non-Hodgkin lymphoma of distinct histological origin

Myron S. Czuczman, Julie M. Vose, Thomas E. Witzig, Pier L. Zinzani, Rena Buckstein, Jonathan Polikoff, Ju Li, Dennis Pietronigro, Annetti Ervin-Haynes, Craig B. Reeder

Research output: Contribution to journalArticle

39 Scopus citations

Abstract

Transformed lymphoma (TL) represents a heterogeneous group of lymphomas with an aggressive course and poor prognosis. We assessed the clinical benefit of single-agent lenalidomide based on histological origin, including transformed follicular lymphoma (tFL) and transformed chronic lymphocytic leukaemia/small lymphocytic lymphoma (tCLL/SLL). Our analysis included 33 patients with TL. Patients received lenalidomide at a median dose of 25mg/d. The overall response rate (ORR) was 46%, with a median response duration of 12·8months after a median follow-up of 5·6months. Median progression-free survival was 5·4months. Among patients with tFL, ORR was 57%, with a median response duration of 12·8months. None of the patients with tCLL/SLL responded to lenalidomide monotherapy. The most common grade 3/4 adverse events were reversible myelosuppression. Our results suggest that the original lymphoma histology (i.e. FL) in TL patients may potentially be associated with response to salvage lenalidomide monotherapy.

Original languageEnglish (US)
Pages (from-to)477-481
Number of pages5
JournalBritish journal of haematology
Volume154
Issue number4
DOIs
StatePublished - Aug 2011

Keywords

  • Lenalidomide
  • Transformed chronic lymphocytic leukaemia
  • Transformed follicular lymphoma
  • Transformed lymphoma
  • Transformed small lymphocytic lymphoma

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non-Hodgkin lymphoma of distinct histological origin'. Together they form a unique fingerprint.

  • Cite this